EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab

Erin L MacMillan iD, Bretta Russell-Schulz, Glaynel Alejo, Christopher Harp, Briana Cameron, Ryan Winger, Sherman Jia, Ann Herman, Jasmyne Kassam, Michael Waine, Irene M Vavasour iD, Helen Cross und 4 weitere

Multiple Sclerosis Journal · 2026

DOI: 10.1177/13524585261456964 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Multiple Sclerosis Journal, 2026. Verfasst von Erin L MacMillan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Department of Radio…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aspartic Acid, Immunologic Factors, Inositol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UBC MS/MRI Research Group, Michael Smith Health Research BC, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Magnetic resonance spectroscopy (MRS) offers non-invasive assessments of neuron–oligodendrocyte coupling and neuroinflammation to monitor treatment response in multiple sclerosis (MS).

Objective

To track changes in N-acetylaspartate and myo-inositol in relapsing MS (RMS) and primary progressive MS (PPMS) patients treated with ocrelizumab over 2 years.

Methods

Single-voxel MRS at 3T was acquired at baseline in 10 healthy controls (HCs), and weeks 0, 12, 24, 52, and 96 in MS participants at a single center.

Results

Baseline myo-inositol was higher in PPMS than RMS ( p = 0.047) and HC ( p = 0.001), and correlated with disability across both MS groups ( r = 0.57, p = 0.0006). Following treatment with ocrelizumab, both RMS and PPMS demonstrated declines in myo-inositol over time, returning toward HC levels (RMS p = 0.016; PPMS p = 0.004). Conversely, N-acetylaspartate was not different between groups and remained stable over time.

Conclusion

Ocrelizumab treatment is associated with declining myo-inositol levels measured by MRS in both RMS and PPMS. Myo-inositol offers a unique biomarker to track resolution of gliosis and reactive microglia with treatment. Furthermore, the relationship between a higher concentration of myo-inositol and greater disability across both MS subtypes at baseline supports the presence of “smouldering inflammation” as a disease process across the spectrum of MS. Clinical Trial: Sub-study of the Ocrelizumab Biomarker Outcome Evaluation (OBOE; ML29966) trial: https://clinicaltrials.gov/study/NCT02688985

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAspartic AcidImmunologic FactorsInositolMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingAdultFemaleHumansMaleMiddle AgedLongitudinal StudiesMagnetic Resonance SpectroscopyTreatment Outcome

Stichwörter der Autor:innen

N-acetylaspartateRelapsing multiple sclerosislongitudinal treatment trackingmagnetic resonance spectroscopymyo-Inositolprimary progressive multiple sclerosis

Substanzen

Antibodies, Monoclonal, HumanizedAspartic AcidImmunologic FactorsInositolN-acetylaspartateocrelizumab

Autor:innen und Institutionen

  • Department of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Department of Radiology, Faculty of Medicine, The University of British Columbia, Vancouv…
  • Department of Radiology, UBC MRI Research Centre, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
  • Genentech, Inc., A Member of the Roche Group, South San Francisco, CA, USA.
  • Division of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
  • Department of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; School of Biomedical Engineering, The University of British Columbia, Vancouver, BC, Canada.
  • Department of Radiology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada; Division of Neurology, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver,…

ORCID-Profile: Erin L MacMillan, Irene M Vavasour, Robert Carruthers, Shannon H Kolind

Förderung

  • UBC MS/MRI Research Group
  • Michael Smith Health Research BC
  • Genentech

Zitieren

APA

MacMillan, E. L., Russell-Schulz, B., Alejo, G., Harp, C., Cameron, B., Winger, R., Jia, S., Herman, A., Kassam, J., Waine, M., Vavasour, I. M., Cross, H., Tam, R., Traboulsee, A. L., Carruthers, R., & Kolind, S. H. (2026). Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261456964

Vancouver

MacMillan EL, Russell-Schulz B, Alejo G, Harp C, Cameron B, Winger R, et al. Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261456964

BibTeX
@article{MacMillan2026,
  author = {MacMillan, Erin L and Russell-Schulz, Bretta and Alejo, Glaynel and Harp, Christopher and Cameron, Briana and Winger, Ryan and Jia, Sherman and Herman, Ann and Kassam, Jasmyne and Waine, Michael and Vavasour, Irene M and Cross, Helen and Tam, Roger and Traboulsee, Anthony L and Carruthers, Robert and Kolind, Shannon H},
  title = {Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab},
  journal = {Multiple Sclerosis Journal},
  year = {2026},
  doi = {10.1177/13524585261456964}
}
Kostenlos starten →